Loading
Lymphoma Diagnosis and Treatment / Cutaneous Lymphoproliferative Disorders Research · Review
Frontiers in Medicine · September 7, 2026
A consensus or society position rather than new primary data.
This narrative review systematically synthesizes adverse event data from Phase II and III trials supporting 14 NCCN-recommended systemic therapies for mycosis fungoides and Sézary syndrome. Toxicity profiles vary substantially by drug class, with distinct risks requiring therapy-specific monitoring and patient counseling; a key clinical challenge is distinguishing drug-induced cutaneous toxicity from active disease progression.
Narrative review of Phase II and III trial safety data. Patients with mycosis fungoides or Sézary syndrome enrolled in trials of NCCN-recommended systemic therapies.. Intervention: Fourteen systemic therapies: antibody-drug conjugates, monoclonal antibodies, HDAC inhibitors, retinoids, antifolates, immunotoxins, cytotoxic chemotherapies, interferons, and immune checkpoint inhibitors..
Fourteen NCCN-recommended systemic agents reviewed, spanning antibody-drug conjugates, monoclonal antibodies, HDAC inhibitors, retinoids, antifolates, immunotoxins, cytotoxic chemotherapies, interferons, and immune checkpoint inhibitors. Brentuximab vedotin defined by peripheral neuropathy as its principal adverse event. Mogamulizumab distinguished by mogamulizumab-associated rash, a treatment-emergent immune reaction that mimics CTCL progression.
Specific AE incidence percentages, severity gradings, discontinuation rates, and confidence intervals not systematically reported in this review. Brentuximab vedotin defined by peripheral neuropathy as its principal adverse event.
Clinicians should use this review to counsel patients on therapy-specific toxicity profiles, select treatments aligned with patient risk factors and tolerability, and implement appropriate monitoring protocols. The distinction between drug-induced cutaneous toxicity and disease progression is emphasized as critical for treatment decisions.
A narrative review synthesizing adverse event profiles across 14 NCCN-recommended systemic therapies for cutaneous T-cell lymphoma, designed to inform clinical treatment selection and monitoring rather than report new efficacy data.
As stated by the source record.
Clinicians should use this review to counsel patients on therapy-specific toxicity profiles, select treatments aligned with patient risk factors and tolerability, and implement appropriate monitoring protocols. The distinction between drug-induced cutaneous toxicity and disease progression is emphasized as critical for treatment decisions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Background Mycosis fungoides (MF) and Sézary syndrome (SS) are the most prevalent subtypes of cutaneous T-cell lymphoma (CTCL). Systemic therapies span multiple drug classes, and as most are administered with palliative intent over prolonged periods, the adverse event (AE) profile of each agent is as clinically important as its efficacy. No comprehensive narrative review has synthesized AE data across all National Comprehensive Cancer Network (NCCN)-recommended systemic therapies for MF/SS. Objectives To summarize and compare the AE profiles of all 14 NCCN guideline-recommended systemic therapies for MF and SS, with emphasis on cutaneous toxicities and their distinction from active disease. Methods Systemic therapies were identified from Version 2.2026 NCCN Guidelines for Cutaneous Lymphomas. Safety data were abstracted from available Phase II and III trials supporting guideline inclusion, with attention to AE frequency, severity, dose-limiting toxicities, and treatment discontinuation rates. PubMed and Scopus were searched for case reports and series capturing rare or delayed toxicities not represented in prospective trials. Data were narratively synthesized given heterogeneity across study designs and reporting practices. Results Fourteen NCCN-recommended systemic agents were reviewed, spanning antibody-drug conjugates, monoclonal antibodies, histone deacetylase (HDAC) inhibitors, retinoids, antifolates, immunotoxins, cytotoxic chemotherapies, interferons, and immune checkpoint inhibitors. Toxicity profiles varied substantially by drug class. Peripheral neuropathy was the defining AE of brentuximab vedotin. Mogamulizumab was distinguished by mogamulizumab-associated rash, a treatment-emergent immune reaction that closely mimics CTCL progression. Bexarotene required proactive management of hypertriglyceridemia and central hypothyroidism. HDAC inhibitors carried gastrointestinal, hematologic, and cardiac risks, while cytotoxic agents posed variable risks of myelosuppression, mucositis, and hepatotoxicity. Immunomodulatory agents introduced risks of opportunistic infection and paradoxical disease flares. Conclusions Systemic therapies for MF/SS carry distinct AE profiles that should inform treatment selection, patient counseling, and monitoring. A recurring challenge is distinguishing cutaneous drug toxicity from CTCL progression, underscoring the importance of therapy-specific toxicity awareness. Standardized AE reporting and patient-centered outcome measures are needed to optimize long-term care in this population.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.